Aisthesis Medical, a healthcare technology company developing AI-powered clinical decision support systems for acute and critical care, today announced the appointment of Dr. Iain Miller as Non-Executive Director and Chair of the Board.
Dr. Miller brings over 30 years of leadership experience across the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has worked extensively across both United Kingdom and United States markets and has founded and led four MedTech companies, including Presymptom Health, a UK Ministry of Defence spinout, where he served as Chief Executive Officer. Under his leadership, Presymptom Health developed InfectiClear®, a novel diagnostic for infectious diseases.
Dr. Miller has also served on the UK’s National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee and contributed to innovation programmes at NHS England and the Medicines and Healthcare products Regulatory Agency (MHRA). He holds a PhD in BioEngineering from the University of Strathclyde, an MBA from the University of Edinburgh, and a BSc in Physics & Electronics from the University of Glasgow. He has published extensively on diagnostic innovation.
The appointment comes at a pivotal time for Aisthesis Medical as the company advances toward CE MDR (Medical Device Regulation) certification for its flagship product, VIOSync®, an explainable AI platform that creates digital patient twins to predict sepsis and clinical deterioration in hospital settings. Dr. Miller’s commercial, technical, and regulatory expertise is expected to strengthen the company’s governance structure and support its next phase of growth, including clinical validation expansion and preparation for broader commercial deployment.
“We are delighted to welcome Dr. Iain Miller to Aisthesis Medical at this critical juncture,” said Dr. Ioannis Gkouzionis, Co-Founder and CEO of Aisthesis Medical. “Iain has navigated the exact journey we’re on, from innovation to regulatory certification to market entry, multiple times across both the UK and US. His deep understanding of regulatory pathways, clinical validation requirements, and hospital commercialization, combined with his experience building robust governance structures, will be invaluable as we transition from development to deployment. His appointment signals our commitment to building Aisthesis Medical for sustainable, scalable growth.”
Dr. Miller commented: “I am excited to join the Board of Aisthesis Medical at a time of strategic focus and momentum. The company’s approach to clinical AI, combining digital patient twin technology with explainable AI architecture, addresses a critical unmet need in sepsis detection and patient deterioration monitoring. VIOSync® has the potential to transform how hospitals identify and intervene in time-sensitive clinical conditions. I look forward to supporting the team in realizing this vision and navigating the regulatory, clinical, and commercial milestones ahead.”
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven sepsis care platform that goes beyond early prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.
Ready to Learn More?
If you’re a hospital, NHS trust, or healthcare investor interested in learning more about VIOSync or our security and compliance posture, we’d love to connect.
📩 Get in touch: https://aisthesismed.com/contact/
🌐 Learn more about VIOSync: https://aisthesismed.com/product/